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We report a possibly unique patient who developed four
different primary malignancies, in the absence of any
detectable germline genetic abnormality or a family his-
tory of malignancy. The patient has also survived for
more than 15 years after local treatments (without
immunotherapy) of cutaneous melanoma metastatic to
her orbit, brain, skeleton and peritoneum. A 68-year-old
White British woman was referred to the Orbital Service
at Moorfields Eye Hospital with a 4-month history of
right proptosis and true binocular diplopia, this being
41 months after having a 0.8-mm superficial spreading
malignant melanoma of her left ankle treated with wide
local resection. She underwent resection of a left frontal
Fig. 1
Imaging of orbital and intracranial disease in a patient with disseminated cutaneous malignant melanoma. (a, b) Orbital computed tomography at
presentation showed a well-defined soft-tissue mass supero-temporally in the right retrobulbar fat. (c) MRI showed no recurrence of orbital disease
14 years after excision of the orbital mass and radiotherapy. (d) MRI showing gliosis at the site of previous surgical excision and radiotherapy for left
frontal metastases, but without disease recurrence at 15 years after treatment of the intracranial disease. (e) Sequencing of DNA extracted from the
patient’s metastatic melanoma excised from her orbit, this showing a heterozygous point mutation (c.A182G; p.Q61R) (arrowed) in exon 3 of NRAS.
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lobe metastasis a year before orbital presentation.
Computed tomographic scan showed a well-defined
Supero-temporal soft-tissue mass in the right retro-
bulbar fat (Fig. 1a and b). The patient underwent anterior
orbitotomy through an upper eyelid skin-crease incision,
with macroscopic excision of the mass, and histological
examination showed infiltrative melanoma compatible
with metastasis from her previous skin malignancy
(Fig. 2). She underwent external beam radiotherapy
(30 Gy in five fractions over 2 weeks) to the right retro-
bulbar tissues.
Three months after the orbitotomy (44 months after the
primary skin tumour), the patient was found to have a right
femoral bony metastasis, which responded well to local
radiotherapy and insertion of an intramedullary femoral
nail. At 57 months after the primary skin lesion, the patient
underwent resection of multiple retroperitoneal deposits
of metastatic melanoma. There has been no further
recurrence of metastatic cutaneous melanoma at 17 years
following removal of the primary tumour (14 years after
orbital presentation) (Fig. 1c and d).
The patient also had a melanoma of soft parts resected
from her left thigh musculature at the age of 35 years. At
age 48, she underwent left lumpectomy, radiotherapy
and axillary nodal clearance for breast adenocarcinoma.
The patient more recently has developed – at age 80 –
squamous cell carcinoma of her scalp, this being treated
with wide local excision; the tumour was remote from any
area of previous periocular radiotherapy.
There is no family history of malignancy, even on
interrogation of an extended family pedigree.
This study received ethics approval from Moorfields Eye
Hospital Biobank ethics board (15/SW/0104). Written,
informed consent was obtained from the family for par-
ticipation in research and from the patient to publish her
clinical history, imaging and genetic results.
DNA was extracted from the orbital tumour by standard
methods and analysed for point mutations in common
driver genes for cutaneous melanoma (BRAF, NRAS,
KRAS) and ocular melanoma (GNAQ, GNA11); primer
sequences and PCR conditions are available upon
request. Sequencing of NRAS exon 3 showed a
heterozygous point mutation (c.A182G; p.Q61R)
(Fig. 1e). Sequencing of orbital tumour DNA was also
performed for genes related to melanoma prognosis
(SF3B1 and EIF1AX ), with no somatic mutations being
found. MLPA analysis for copy number variation
indicated disomy of chromosome 3, with gain of
chromosome 6p.
Genomic DNA extracted from peripheral blood under
standard conditions was analysed by next-generation
sequencing [Hereditary Cancer Syndromes, Comprehensive
Diagnostics (ID 93.00); MGZ, Munich, Germany] – this
being a multigene diagnostic panel testing for mutations in
94 genes that have been associated with familial-cancer
or multiple-cancer syndromes. No germline mutations were
shown for this patient.
Our patient is enigmatic on two counts: first, she has
survived a perhaps unparalleled period of more than
15 years with cutaneous melanoma metastatic to the
orbit, bone, peritoneum and brain. Second, she has had
four different primary malignancies, these being cuta-
neous melanoma, melanoma of soft parts, breast adeno-
carcinoma and cutaneous squamous cell carcinoma.
Metastatic malignant melanoma has a poor prognosis,
with the 5-year survival (with or without residual disease)
for stage IV cutaneous melanoma being 15–20%, and
about 10% survival by 10 years [1]. Tumour metastases to
the brain are associated with significant neurological
deficit and a very poor survival – less than 8% having a
2-year survival [2] and, without treatment, cerebral
metastatic melanoma has a dismal prognosis, with a
median survival of 3 months [3]. The use of BRAF
inhibitors possibly improves the outcome for metastatic
melanoma treated with local radiotherapy [4–9], although
these retrospective clinical studies are susceptible to
selection bias [10].
Remarkably, our patient remains well at 15 years after
local resection and radiotherapy (without immunother-
apy) for cutaneous melanoma metastatic deep in her left
frontal lobe, as well as metastatic deposits in the orbit,
femur and retroperitoneum. There are sporadic case
reports of patients with long survival following surgical
excision of intracerebral metastases, but these are very
rare. For example, a case reported in 1950 reports survival
Fig. 2
Light micrograph of resected orbital tumour showing a population of
pleomorphic cells with large nuclei and prominent nucleoli (scale
bar=40 µm). Pigmentation is present, consistent with metastatic
cutaneous melanoma. The inset panel shows immunoreactivity
for HMB45.
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of at least 3 years 9 months following the removal of
melanoma deposit in the left frontal lobe [11]. Two fur-
ther cases of prolonged survival were reported in 1968,
with one patient living for 14 years and a second patient
surviving 10 years, both following surgical excision of
solitary intracranial metastases [12]. More recently, a case
reported disease-free survival of 16 years following sur-
gical resection, stereotactic radiation and chemotherapy
for multiple intracranial melanoma lesions [13]. It is clear,
then, that on rare occasions, surgical metastasectomy –
with or without adjuvant therapy – can be associated
with surprisingly good outcomes. In this case, the patient
underwent metastasectomy at three sites (retro-
peritoneal, intracerebral and orbital). A large analysis of
over 4000 patients with metastatic cutaneous melanoma
suggested that metastasectomy is beneficial; it was shown
that –compared with patients who did not undergo the
procedure – patients who underwent metastasis resection
had an improved median survival (12 vs. 5 months) as
well as higher percentage of 5-year overall survival (16 vs.
7%) [14]. It is clear, though, that the case reported here is
an outlier to these survival rates and thus metastasectomy
cannot be the sole factor that has played a role in her long
survival.
It is interesting to speculate whether the identified
tumour mutation (NRAS p.Q61R) played a role in the
long survival in our patient. NRAS mutations occur in
13–25% of cutaneous melanoma [15,16], the p.Q61R
change accounting for ∼ 35% of NRAS-mutated tumours
[17]. Advanced cutaneous melanoma containing NRAS
mutations have a worse prognosis, with shorter median
survival and more aggressive disease [18,19]. This sug-
gests that our patient’s long survival is not attributable to
her tumour driver mutation in NRAS. Furthermore, our
patient did not have a mutation in SF3B1 or EIF1AX,
two mutations associated with a better prognosis in uveal
melanoma – although only rarely reported in cutaneous
melanoma [20,21]. It is, therefore, plausible that our
patient’s tumour has a currently unidentified protective
mutation and next-generation sequencing of the tumour
DNA might be valuable here.
MLPA analysis showed normal disomy 3, but gain
of chromosome 6p in our patient’s orbital tumour.
Aberrations of chromosome 6 are the most common
cytogenetic change in melanomas, with 6p gain in up to
85% of uveal melanomas, and more than 90% of sinonasal
and cutaneous melanomas [22]. Gain of chromosome 6p
(with chromosome 3 disomy) occurs in approximately
one-third of uveal melanomas and is associated with
better survival [23,24]. However, gain of chromosome 6p
would normally confer a poorer prognosis in cutaneous
melanoma and several other tumours such as colorectal
and bladder carcinoma, and sarcoma [22,25]. The median
survival for patients with melanoma metastatic to the
orbit is 24 months after orbital diagnosis, but some
patients can have a very long survival (of up to 33 years)
[26]. However, tumours of cutaneous origin were repor-
ted to have the worst survival of all melanoma metastatic
to the orbit and thus, again, our patient’s extremely long
survival appears to be unusual [26].
The second enigmatic feature of our patient is her mul-
tiple primary malignancies, including the particularly rare
malignant melanoma of soft parts. With her also devel-
oping nonfamilial breast cancer before the age of
50 years, cutaneous melanoma and squamous cell carci-
noma, there was a high clinical suspicion that she would
carry a germline mutation predisposing to malignancy;
notably, however, there was no history suggesting a
familial-cancer predisposition syndrome.
The patient’s germline DNA did not show any mutations
in 94 known cancer genes, which raises two possible
scenarios: first, our patient might just have been
‘unlucky’ and – without any predisposing germline
mutation – has developed random somatic mutations
giving rise to four separate malignancies. The second
possibility is that she harbours an unidentified germline
mutation in a very rare oncogene that is not included in
the comprehensive diagnostic panel; whole-exome
sequencing of her germline DNA might reveal a novel
oncogenic or tumour-suppressor gene.
In summary, this patient is a unique case of cutaneous
melanoma with multiple metastases, who has survived for
a remarkable 14 years after orbital and intracranial disease –
despite being treated before the introduction of
immunotherapy. Furthermore, she has had four separate
primary malignancies – without apparent familial or germline
predisposition to cancer.
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